Trans-MSC can differentiate in vitro into a variety of cell types including osteoblasts (bone), chondrocytes (cartilage), adipocytes (fat), myocytes (muscle), neurons (nerve) etc. The harvested primary cells are processed and configured to make them induced pluripotent type while characterized by the expression of biomarkers : SSEA4, CD90, CD105, and CD73, and by the absence of CD34, CD14 or CD11b, CD79alpha or CD19, CD45, and HLA-DR surface molecules; they are adherent to plastic when maintained in standard culture conditions, and form colonies.
TRANS-MSC platform is harvested from freshly collected source and induced by a proprietary process to the desired configuration/ specifications and packaging format. Cells are produced in batches; they are ready-to-use, and no culturing procedure is required.
Care is taken to ensure the consent is in place, while handling procedures are compliant with government and Institutional Ethics Committee (IEC). Donors are tested for infection by HIV-1, HIV-2, HBV, HCV, Mycoplasma, Bacteria, Yeast and Fungi before collection. Cells are processed batch wise to be bioburden free.
TRANS-MSC has applications in exploratory evaluations such as high throughput screening (HTS) of test materials, drugs, chemicals, or biologics, for transdifferentiation studies, efficacy, in vitro ADME. Measured end-points of assays performed on the in vitro system are of human relevance, i.e. are predictive of human biology, because the cells reproduce, to a close approximation, the human biochemical milieu; assay readouts may be obtained at the microscopic, transcriptomic, or proteomic levels.
Disclaimer: Product for in vitro research use only. Not approved for diagnostic, therapeutic, or clinical applications. Not approved for human or veterinary use in vivo.